Antibiotics and Antimycotics Market Size and Forecast, Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Drug Class, Indication, Route of Administration, Distribution Channel, and Geography

Description

List of Tables

The global antibiotics and antimycotics market is anticipated to grow from US$ 61.20 billion in 2023 and is projected to reach US$ 91.54 billion by 2031; it is expected to register a CAGR of 5.2% during 2023-2031. The antibiotics and antimycotics market growth is attributed to the increasing geriatric population, the growing burden of dental diseases, and the surging demand for cosmetic dentistry.

Antibiotics and antimycotics are antimicrobial agents targeting different types of pathogens. Antibiotics are further classified into bactericidal antibiotics, which kill bacteria (penicillins and cephalosporins), and bacteriostatic antibiotics, which inhibit bacterial growth (tetracyclines and macrolides). Antibiotics are widely used to treat bacterial infections, but their effectiveness is challenged by the rise of antibiotic-resistant strains. Antimycotics are specifically designed to combat fungal infections. They work by targeting various aspects of fungal cell structure or metabolism. Common classes of antimycotics include azoles (fluconazole), polyenes (amphotericin B), and echinocandins (caspofungin). Antimycotics are essential in treating conditions caused by fungi, such as candidiasis and aspergillosis.

The North America antibiotics and antimycotics market is segmented into the US, Canada, and Mexico. The market is mainly driven by the rising prevalence of bacterial and fungal infections, the presence of developed healthcare infrastructure, and the availability of a wide range of antibiotics and antimycotics for the treatment of such infections. Additionally, the rise in product launches, approvals, and other strategic initiatives by major players is expected to create opportunities for the market growth during the forecast period.

In North America, the US is the largest market for antibiotics and antimycotics. The US antibiotics and antimycotics market growth is driven by the increasing prevalence of fungal and bacterial infections and the growing need for effective treatment options. Pneumonia is the most common respiratory infection in the US. According to Verywell Health Journal 2024 report, every year, ~1.5 million adults in the US are diagnosed with pneumonia; of which around 1 million are admitted to hospitals while 50,000 people die due to pneumonia or related complications. Amoxicillin and azithromycin are the most commonly used antibiotics prescribed in the US in outpatient settings for the treatment of bacterial infections. In addition, with ongoing advancements in pharmaceutical research and technology, the development of new antibiotics and antifungal agents has gained momentum, responding to the growing concerns about antibiotic resistance and the need for innovative therapies. Moreover, the growing awareness about the importance of antimicrobial stewardship programs has led to a more cautious approach to antibiotic prescription, prompting a shift toward targeted therapies and combination treatments. This is particularly evident in hospital settings, where the growing incidence of hospital-acquired infections necessitates the use of potent antimicrobials.

Key players are taking strategic initiatives such as product launches, product approvals, and collaborations, which are expected to support the market growth during the forecast period. For instance, in April 2024, the US Food and Drug Administration (FDA) approved Zevtera (ceftobiprole medocaril sodium for injection) for the treatment of adults suffering from Staphylococcus aureus bloodstream infections (SAB), including those with right-sided infective endocarditis and adults suffering from acute bacterial skin and skin structure infections (ABSSSI). Additionally, in March 2023, The US FDA approved REZZAYO (rezafungin for injection) for the treatment of candidemia and invasive candidiasis.

Technological Advancements in Product Development and Treatment Delivery Approaches

The pharmaceutical industry emphasizes incorporating intelligent technologies such as deep learning, artificial intelligence (AI), and machine learning in the development of new antibiotics. Researchers are working to establish tools and platforms for identifying new active compounds. Harnessing the capabilities of novel technologies in new antibiotic discoveries is expected to change the overall course of antibiotic and antimycotic development and approval processes.

Developing antibiotics for Gram-negative bacteria poses a significant challenge to researchers, and many drugs are still in the development phases. Limited permeability across the envelope of these bacteria due to nutrient-specific protein channels (porins) restricts the movement of non-essential molecules (including antibiotics) across membranes. Considering the difficulties around cell membrane permeability, researchers have developed a new Computational Antibiotic Screening Platform (CLASP) that helps identify potential drug molecules based on the analysis of porins. Advantages such as coarse grain (CG) resolution, advanced sampling techniques, and a parallel computing environment maximize the performance of CLASPs. The platform provides complete thermodynamic and kinetic results for a potential drug molecule under study in a few hours. It also helps understand or identify small molecule libraries that yield structure-property relationships to discover antibiotics with high permeability.

There is a rising inclination toward precision medicine approaches that involve adjusting antibiotic treatments based on patients' genetic profiles and resistance patterns that are common among large populations. Such a revolution would improve drugs' functionality while ensuring minimal adverse effects and curbing the development of resistance. Phage therapy has emerged as another novel approach that involves a potential combination of traditional microbial treatments with bacteriophages to target and destroy antibiotic-resistant pathogens. Promising recent advancements in gene-editing technologies, such as CRISPR, has the ability to further enhance the prospects of phage therapy. Thus, technological advancements in drug development and treatment delivery approaches are expected to bring new growth trends in the antibiotics and antimycotics market growth in the coming years.

Antibiotics and Antimycotics Market: Competitive Landscape and Key Developments

Pfizer Inc, Novartis AG, Sanofi SA, F. Hoffmann-La Roche Ltd, Merck & Co Inc, GSK Plc, Johnson & Johnson, Cipla Ltd, Bayer AG, AbbVie Inc, and Astellas Pharma Inc. are among the key companies operating in the antibiotics and antimycotics market.

The US Food and Drug Administration, National Institute of Health, United Nations International Children's Emergency Fund (UNICEF), World Health Organization (WHO), National Notifiable Diseases Surveillance System are among the primary and secondary sources referred to while preparing the antibiotics and antimycotics market report.

Product Code: TIPRE00021878

1. Introduction

1.1 The Insight Partners Research Report Guidance
1.2 Market Segmentation

2. Executive Summary

2.1 Key Insights

3. Research Methodology

3.1 Secondary Research
3.2 Primary Research
- 3.2.1 Hypothesis formulation:
- 3.2.2 Macro-economic factor analysis:
- 3.2.3 Developing base number:
- 3.2.4 Data Triangulation:
- 3.2.5 Country level data:

4. Antibiotics and Antimycotics Market Landscape

4.1 Overview
4.2 PEST Analysis

5. Antibiotics and Antimycotics Market - Key Market Dynamics

5.1 Antibiotics and Antimycotics Market - Key Market Dynamics
5.2 Market Drivers:
- 5.2.1 Increasing Prevalence of Infectious Diseases
- 5.2.2 Growing Awareness About Fungal Infections
5.3 Market Restraints
- 5.3.1 Antimicrobial Resistance, Financial Barriers, and Extensive Regulatory Processes
5.4 Market Opportunities
- 5.4.1 Ongoing Funding and Research & Development Initiatives
5.5 Future Trends
- 5.5.1 Technological Advancements in Product Development and Treatment Delivery Approaches
5.6 Impact of Drivers and Restraints:

6. Antibiotics and Antimycotics Market - Global Market Analysis

6.1 Antibiotics and Antimycotics Market Revenue (US$ Million), 2021-2031
6.2 Antibiotics and Antimycotics Market Forecast Analysis

7. Antibiotics and Antimycotics Market Analysis - by Drug Class

7.1 Penicillin
- 7.1.1 Overview
- 7.1.2 Penicillin: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031 (US$ Million)
7.2 Cephalosporines
- 7.2.1 Overview
- 7.2.2 Cephalosporines: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031 (US$ Million)
7.3 Carbapenems
- 7.3.1 Overview
- 7.3.2 Carbapenems: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031 (US$ Million)
7.4 Macrolides
- 7.4.1 Overview
- 7.4.2 Macrolides: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031 (US$ Million)
7.5 Aminoglycosides
- 7.5.1 Overview
- 7.5.2 Aminoglycosides: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031 (US$ Million)
7.6 Quinolones
- 7.6.1 Overview
- 7.6.2 Quinolones: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031 (US$ Million)
7.7 Sulfonamides
- 7.7.1 Overview
- 7.7.2 Sulfonamides: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031 (US$ Million)
7.8 Tetracyclines
- 7.8.1 Overview
- 7.8.2 Tetracyclines: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031 (US$ Million)
7.9 Azoles
- 7.9.1 Overview
- 7.9.2 Azoles: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031 (US$ Million)
7.10 Others
- 7.10.1 Overview
- 7.10.2 Others: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031 (US$ Million)

8. Antibiotics and Antimycotics Market Analysis - by Indication

8.1 Skin Infections
- 8.1.1 Overview
- 8.1.2 Skin Infections: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031 (US$ Million)
8.2 Respiratory Infections
- 8.2.1 Overview
- 8.2.2 Respiratory Infections: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031 (US$ Million)
8.3 Urinary Tract Infections (UTI)
- 8.3.1 Overview
- 8.3.2 Urinary Tract Infections (UTI): Antibiotics and Antimycotics Market - Revenue and Forecast to 2031 (US$ Million)
8.4 Septicemia
- 8.4.1 Overview
- 8.4.2 Septicemia: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031 (US$ Million)
8.5 Ear Infections
- 8.5.1 Overview
- 8.5.2 Ear Infections: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031 (US$ Million)
8.6 Gastrointestinal Infections
- 8.6.1 Overview
- 8.6.2 Gastrointestinal Infections: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031 (US$ Million)
8.7 Others
- 8.7.1 Overview
- 8.7.2 Others: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031 (US$ Million)

9. Antibiotics and Antimycotics Market Analysis - by Route Of Administration

9.1 Oral
- 9.1.1 Overview
- 9.1.2 Oral: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031 (US$ Million)
9.2 Topical
- 9.2.1 Overview
- 9.2.2 Topical: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031 (US$ Million)
9.3 Others
- 9.3.1 Overview
- 9.3.2 Others: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031 (US$ Million)

10. Antibiotics and Antimycotics Market Analysis - by Distribution Channel

10.1 Hospital Pharmacies
- 10.1.1 Overview
- 10.1.2 Hospital Pharmacies: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031 (US$ Million)
10.2 Retail Pharmacies
- 10.2.1 Overview
- 10.2.2 Retail Pharmacies: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031 (US$ Million)
10.3 Online Pharmacies
- 10.3.1 Overview
- 10.3.2 Online Pharmacies: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031 (US$ Million)

11. Antibiotics and Antimycotics Market - Geographical Analysis

11.1 North America
- 11.1.1 North America Antibiotics and Antimycotics Market Overview
- 11.1.2 North America: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031 (US$ Million)
  - 11.1.2.1 North America: Antibiotics and Antimycotics Market - Revenue and Forecast Analysis - by Drug Class
  - 11.1.2.2 North America: Antibiotics and Antimycotics Market - Revenue and Forecast Analysis - by Indication
  - 11.1.2.3 North America: Antibiotics and Antimycotics Market - Revenue and Forecast Analysis - by Route Of Administration
  - 11.1.2.4 North America: Antibiotics and Antimycotics Market - Revenue and Forecast Analysis - by Distribution Channel
- 11.1.3 North America: Antibiotics and Antimycotics Market - Revenue and Forecast Analysis - by Country
  - 11.1.3.1 United States: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031 (US$ Million)
    - 11.1.3.1.1 United States: Antibiotics and Antimycotics Market Breakdown, by Drug Class
    - 11.1.3.1.2 United States: Antibiotics and Antimycotics Market Breakdown, by Indication
    - 11.1.3.1.3 United States: Antibiotics and Antimycotics Market Breakdown, by Route Of Administration
    - 11.1.3.1.4 United States: Antibiotics and Antimycotics Market Breakdown, by Distribution Channel
  - 11.1.3.2 Canada: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031 (US$ Million)
    - 11.1.3.2.1 Canada: Antibiotics and Antimycotics Market Breakdown, by Drug Class
    - 11.1.3.2.2 Canada: Antibiotics and Antimycotics Market Breakdown, by Indication
    - 11.1.3.2.3 Canada: Antibiotics and Antimycotics Market Breakdown, by Route Of Administration
    - 11.1.3.2.4 Canada: Antibiotics and Antimycotics Market Breakdown, by Distribution Channel
  - 11.1.3.3 Mexico: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031 (US$ Million)
    - 11.1.3.3.1 Mexico: Antibiotics and Antimycotics Market Breakdown, by Drug Class
    - 11.1.3.3.2 Mexico: Antibiotics and Antimycotics Market Breakdown, by Indication
    - 11.1.3.3.3 Mexico: Antibiotics and Antimycotics Market Breakdown, by Route Of Administration
    - 11.1.3.3.4 Mexico: Antibiotics and Antimycotics Market Breakdown, by Distribution Channel
11.2 Europe
- 11.2.1 Europe Antibiotics and Antimycotics Market Overview
- 11.2.2 Europe: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031 (US$ Million)
  - 11.2.2.1 Europe: Antibiotics and Antimycotics Market - Revenue and Forecast Analysis - by Drug Class
  - 11.2.2.2 Europe: Antibiotics and Antimycotics Market - Revenue and Forecast Analysis - by Indication
  - 11.2.2.3 Europe: Antibiotics and Antimycotics Market - Revenue and Forecast Analysis - by Route Of Administration
  - 11.2.2.4 Europe: Antibiotics and Antimycotics Market - Revenue and Forecast Analysis - by Distribution Channel
- 11.2.3 Europe: Antibiotics and Antimycotics Market - Revenue and Forecast Analysis - by Country
  - 11.2.3.1 Germany: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031 (US$ Million)
    - 11.2.3.1.1 Germany: Antibiotics and Antimycotics Market Breakdown, by Drug Class
    - 11.2.3.1.2 Germany: Antibiotics and Antimycotics Market Breakdown, by Indication
    - 11.2.3.1.3 Germany: Antibiotics and Antimycotics Market Breakdown, by Route Of Administration
    - 11.2.3.1.4 Germany: Antibiotics and Antimycotics Market Breakdown, by Distribution Channel
  - 11.2.3.2 France: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031 (US$ Million)
    - 11.2.3.2.1 France: Antibiotics and Antimycotics Market Breakdown, by Drug Class
    - 11.2.3.2.2 France: Antibiotics and Antimycotics Market Breakdown, by Indication
    - 11.2.3.2.3 France: Antibiotics and Antimycotics Market Breakdown, by Route Of Administration
    - 11.2.3.2.4 France: Antibiotics and Antimycotics Market Breakdown, by Distribution Channel
  - 11.2.3.3 Spain: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031 (US$ Million)
    - 11.2.3.3.1 Spain: Antibiotics and Antimycotics Market Breakdown, by Drug Class
    - 11.2.3.3.2 Spain: Antibiotics and Antimycotics Market Breakdown, by Indication
    - 11.2.3.3.3 Spain: Antibiotics and Antimycotics Market Breakdown, by Route Of Administration
    - 11.2.3.3.4 Spain: Antibiotics and Antimycotics Market Breakdown, by Distribution Channel
  - 11.2.3.4 Italy: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031 (US$ Million)
    - 11.2.3.4.1 Italy: Antibiotics and Antimycotics Market Breakdown, by Drug Class
    - 11.2.3.4.2 Italy: Antibiotics and Antimycotics Market Breakdown, by Indication
    - 11.2.3.4.3 Italy: Antibiotics and Antimycotics Market Breakdown, by Route Of Administration
    - 11.2.3.4.4 Italy: Antibiotics and Antimycotics Market Breakdown, by Distribution Channel
  - 11.2.3.5 United Kingdom: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031 (US$ Million)
    - 11.2.3.5.1 United Kingdom: Antibiotics and Antimycotics Market Breakdown, by Drug Class
    - 11.2.3.5.2 United Kingdom: Antibiotics and Antimycotics Market Breakdown, by Indication
    - 11.2.3.5.3 United Kingdom: Antibiotics and Antimycotics Market Breakdown, by Route Of Administration
    - 11.2.3.5.4 United Kingdom: Antibiotics and Antimycotics Market Breakdown, by Distribution Channel
  - 11.2.3.6 Rest of Europe: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031 (US$ Million)
    - 11.2.3.6.1 Rest of Europe: Antibiotics and Antimycotics Market Breakdown, by Drug Class
    - 11.2.3.6.2 Rest of Europe: Antibiotics and Antimycotics Market Breakdown, by Indication
    - 11.2.3.6.3 Rest of Europe: Antibiotics and Antimycotics Market Breakdown, by Route Of Administration
    - 11.2.3.6.4 Rest of Europe: Antibiotics and Antimycotics Market Breakdown, by Distribution Channel
11.3 Asia Pacific
- 11.3.1 Asia Pacific Antibiotics and Antimycotics Market Overview
- 11.3.2 Asia Pacific: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031 (US$ Million)
  - 11.3.2.1 Asia Pacific: Antibiotics and Antimycotics Market - Revenue and Forecast Analysis - by Drug Class
  - 11.3.2.2 Asia Pacific: Antibiotics and Antimycotics Market - Revenue and Forecast Analysis - by Indication
  - 11.3.2.3 Asia Pacific: Antibiotics and Antimycotics Market - Revenue and Forecast Analysis - by Route Of Administration
  - 11.3.2.4 Asia Pacific: Antibiotics and Antimycotics Market - Revenue and Forecast Analysis - by Distribution Channel
- 11.3.3 Asia Pacific: Antibiotics and Antimycotics Market - Revenue and Forecast Analysis - by Country
  - 11.3.3.1 China: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031 (US$ Million)
    - 11.3.3.1.1 China: Antibiotics and Antimycotics Market Breakdown, by Drug Class
    - 11.3.3.1.2 China: Antibiotics and Antimycotics Market Breakdown, by Indication
    - 11.3.3.1.3 China: Antibiotics and Antimycotics Market Breakdown, by Route Of Administration
    - 11.3.3.1.4 China: Antibiotics and Antimycotics Market Breakdown, by Distribution Channel
  - 11.3.3.2 Japan: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031 (US$ Million)
    - 11.3.3.2.1 Japan: Antibiotics and Antimycotics Market Breakdown, by Drug Class
    - 11.3.3.2.2 Japan: Antibiotics and Antimycotics Market Breakdown, by Indication
    - 11.3.3.2.3 Japan: Antibiotics and Antimycotics Market Breakdown, by Route Of Administration
    - 11.3.3.2.4 Japan: Antibiotics and Antimycotics Market Breakdown, by Distribution Channel
  - 11.3.3.3 India: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031 (US$ Million)
    - 11.3.3.3.1 India: Antibiotics and Antimycotics Market Breakdown, by Drug Class
    - 11.3.3.3.2 India: Antibiotics and Antimycotics Market Breakdown, by Indication
    - 11.3.3.3.3 India: Antibiotics and Antimycotics Market Breakdown, by Route Of Administration
    - 11.3.3.3.4 India: Antibiotics and Antimycotics Market Breakdown, by Distribution Channel
  - 11.3.3.4 Australia: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031 (US$ Million)
    - 11.3.3.4.1 Australia: Antibiotics and Antimycotics Market Breakdown, by Drug Class
    - 11.3.3.4.2 Australia: Antibiotics and Antimycotics Market Breakdown, by Indication
    - 11.3.3.4.3 Australia: Antibiotics and Antimycotics Market Breakdown, by Route Of Administration
    - 11.3.3.4.4 Australia: Antibiotics and Antimycotics Market Breakdown, by Distribution Channel
  - 11.3.3.5 South Korea: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031 (US$ Million)
    - 11.3.3.5.1 South Korea: Antibiotics and Antimycotics Market Breakdown, by Drug Class
    - 11.3.3.5.2 South Korea: Antibiotics and Antimycotics Market Breakdown, by Indication
    - 11.3.3.5.3 South Korea: Antibiotics and Antimycotics Market Breakdown, by Route Of Administration
    - 11.3.3.5.4 South Korea: Antibiotics and Antimycotics Market Breakdown, by Distribution Channel
  - 11.3.3.6 Rest of APAC: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031 (US$ Million)
    - 11.3.3.6.1 Rest of APAC: Antibiotics and Antimycotics Market Breakdown, by Drug Class
    - 11.3.3.6.2 Rest of APAC: Antibiotics and Antimycotics Market Breakdown, by Indication
    - 11.3.3.6.3 Rest of APAC: Antibiotics and Antimycotics Market Breakdown, by Route Of Administration
    - 11.3.3.6.4 Rest of APAC: Antibiotics and Antimycotics Market Breakdown, by Distribution Channel
11.4 Middle East and Africa
- 11.4.1 Middle East and Africa Antibiotics and Antimycotics Market Overview
- 11.4.2 Middle East and Africa: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031 (US$ Million)
  - 11.4.2.1 Middle East and Africa: Antibiotics and Antimycotics Market - Revenue and Forecast Analysis - by Drug Class
  - 11.4.2.2 Middle East and Africa: Antibiotics and Antimycotics Market - Revenue and Forecast Analysis - by Indication
  - 11.4.2.3 Middle East and Africa: Antibiotics and Antimycotics Market - Revenue and Forecast Analysis - by Route Of Administration
  - 11.4.2.4 Middle East and Africa: Antibiotics and Antimycotics Market - Revenue and Forecast Analysis - by Distribution Channel
- 11.4.3 Middle East and Africa: Antibiotics and Antimycotics Market - Revenue and Forecast Analysis - by Country
  - 11.4.3.1 Saudi Arabia: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031 (US$ Million)
    - 11.4.3.1.1 Saudi Arabia: Antibiotics and Antimycotics Market Breakdown, by Drug Class
    - 11.4.3.1.2 Saudi Arabia: Antibiotics and Antimycotics Market Breakdown, by Indication
    - 11.4.3.1.3 Saudi Arabia: Antibiotics and Antimycotics Market Breakdown, by Route Of Administration
    - 11.4.3.1.4 Saudi Arabia: Antibiotics and Antimycotics Market Breakdown, by Distribution Channel
  - 11.4.3.2 South Africa: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031 (US$ Million)
    - 11.4.3.2.1 South Africa: Antibiotics and Antimycotics Market Breakdown, by Drug Class
    - 11.4.3.2.2 South Africa: Antibiotics and Antimycotics Market Breakdown, by Indication
    - 11.4.3.2.3 South Africa: Antibiotics and Antimycotics Market Breakdown, by Route Of Administration
    - 11.4.3.2.4 South Africa: Antibiotics and Antimycotics Market Breakdown, by Distribution Channel
  - 11.4.3.3 United Arab Emirates: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031 (US$ Million)
    - 11.4.3.3.1 United Arab Emirates: Antibiotics and Antimycotics Market Breakdown, by Drug Class
    - 11.4.3.3.2 United Arab Emirates: Antibiotics and Antimycotics Market Breakdown, by Indication
    - 11.4.3.3.3 United Arab Emirates: Antibiotics and Antimycotics Market Breakdown, by Route Of Administration
    - 11.4.3.3.4 United Arab Emirates: Antibiotics and Antimycotics Market Breakdown, by Distribution Channel
  - 11.4.3.4 Rest of Middle East and Africa: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031 (US$ Million)
    - 11.4.3.4.1 Rest of Middle East and Africa: Antibiotics and Antimycotics Market Breakdown, by Drug Class
    - 11.4.3.4.2 Rest of Middle East and Africa: Antibiotics and Antimycotics Market Breakdown, by Indication
    - 11.4.3.4.3 Rest of Middle East and Africa: Antibiotics and Antimycotics Market Breakdown, by Route Of Administration
    - 11.4.3.4.4 Rest of Middle East and Africa: Antibiotics and Antimycotics Market Breakdown, by Distribution Channel
11.5 South and Central America
- 11.5.1 South and Central America Antibiotics and Antimycotics Market Overview
- 11.5.2 South and Central America: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031 (US$ Million)
  - 11.5.2.1 South and Central America: Antibiotics and Antimycotics Market - Revenue and Forecast Analysis - by Drug Class
  - 11.5.2.2 South and Central America: Antibiotics and Antimycotics Market - Revenue and Forecast Analysis - by Indication
  - 11.5.2.3 South and Central America: Antibiotics and Antimycotics Market - Revenue and Forecast Analysis - by Route Of Administration
  - 11.5.2.4 South and Central America: Antibiotics and Antimycotics Market - Revenue and Forecast Analysis - by Distribution Channel
- 11.5.3 South and Central America: Antibiotics and Antimycotics Market - Revenue and Forecast Analysis - by Country
  - 11.5.3.1 Brazil: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031 (US$ Million)
    - 11.5.3.1.1 Brazil: Antibiotics and Antimycotics Market Breakdown, by Drug Class
    - 11.5.3.1.2 Brazil: Antibiotics and Antimycotics Market Breakdown, by Indication
    - 11.5.3.1.3 Brazil: Antibiotics and Antimycotics Market Breakdown, by Route Of Administration
    - 11.5.3.1.4 Brazil: Antibiotics and Antimycotics Market Breakdown, by Distribution Channel
  - 11.5.3.2 Argentina: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031 (US$ Million)
    - 11.5.3.2.1 Argentina: Antibiotics and Antimycotics Market Breakdown, by Drug Class
    - 11.5.3.2.2 Argentina: Antibiotics and Antimycotics Market Breakdown, by Indication
    - 11.5.3.2.3 Argentina: Antibiotics and Antimycotics Market Breakdown, by Route Of Administration
    - 11.5.3.2.4 Argentina: Antibiotics and Antimycotics Market Breakdown, by Distribution Channel
  - 11.5.3.3 Rest of South and Central America: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031 (US$ Million)
    - 11.5.3.3.1 Rest of South and Central America: Antibiotics and Antimycotics Market Breakdown, by Drug Class
    - 11.5.3.3.2 Rest of South and Central America: Antibiotics and Antimycotics Market Breakdown, by Indication
    - 11.5.3.3.3 Rest of South and Central America: Antibiotics and Antimycotics Market Breakdown, by Route Of Administration
    - 11.5.3.3.4 Rest of South and Central America: Antibiotics and Antimycotics Market Breakdown, by Distribution Channel

12. Antibiotics and Antimycotics Market - Industry Landscape

12.1 Overview
12.2 Growth Strategies in Antibiotics and Antimycotics Market
12.3 Organic Growth Strategies
- 12.3.1 Overview
12.4 Inorganic Growth Strategies
- 12.4.1 Overview

13. Company Profiles

13.1 Pfizer Inc
- 13.1.1 Key Facts
- 13.1.2 Business Description
- 13.1.3 Products and Services
- 13.1.4 Financial Overview
- 13.1.5 SWOT Analysis
- 13.1.6 Key Developments
13.2 Novartis AG
- 13.2.1 Key Facts
- 13.2.2 Business Description
- 13.2.3 Products and Services
- 13.2.4 Financial Overview
- 13.2.5 SWOT Analysis
- 13.2.6 Key Developments
13.3 Sanofi SA
- 13.3.1 Key Facts
- 13.3.2 Business Description
- 13.3.3 Products and Services
- 13.3.4 Financial Overview
- 13.3.5 SWOT Analysis
- 13.3.6 Key Developments
13.4 F. Hoffmann-La Roche Ltd
- 13.4.1 Key Facts
- 13.4.2 Business Description
- 13.4.3 Products and Services
- 13.4.4 Financial Overview
- 13.4.5 SWOT Analysis
- 13.4.6 Key Developments
13.5 Merck & Co Inc
- 13.5.1 Key Facts
- 13.5.2 Business Description
- 13.5.3 Products and Services
- 13.5.4 Financial Overview
- 13.5.5 SWOT Analysis
- 13.5.6 Key Developments
13.6 GSK Plc
- 13.6.1 Key Facts
- 13.6.2 Business Description
- 13.6.3 Products and Services
- 13.6.4 Financial Overview
- 13.6.5 SWOT Analysis
- 13.6.6 Key Developments
13.7 Johnson & Johnson
- 13.7.1 Key Facts
- 13.7.2 Business Description
- 13.7.3 Products and Services
- 13.7.4 Financial Overview
- 13.7.5 SWOT Analysis
- 13.7.6 Key Developments
13.8 Cipla Ltd
- 13.8.1 Key Facts
- 13.8.2 Business Description
- 13.8.3 Products and Services
- 13.8.4 Financial Overview
- 13.8.5 SWOT Analysis
- 13.8.6 Key Developments
13.9 Bayer AG
- 13.9.1 Key Facts
- 13.9.2 Business Description
- 13.9.3 Products and Services
- 13.9.4 Financial Overview
- 13.9.5 SWOT Analysis
- 13.9.6 Key Developments
13.10 AbbVie Inc
- 13.10.1 Key Facts
- 13.10.2 Business Description
- 13.10.3 Products and Services
- 13.10.4 Financial Overview
- 13.10.5 SWOT Analysis
- 13.10.6 Key Developments
13.11 Astellas Pharma Inc
- 13.11.1 Key Facts
- 13.11.2 Business Description
- 13.11.3 Products and Services
- 13.11.4 Financial Overview
- 13.11.5 SWOT Analysis
- 13.11.6 Key Developments

14. Appendix

14.1 About The Insight Partners
14.2 Glossary of Terms